[PDF] Top 20 El bolero y la nueva canción de amor

... Regular communication between referring physicians and the treating nuclear medicine physicians will establish solid working relationships and keep all parties informed of pa- tients’ progress. This could be achieved via ... See full document

... the treatment with Radium-223 at the INMM in order to improve the quality of the thera- peutic ...this treatment, the patients create just one homogenous group of men with ...the ... See full document

... with metastatic castration-resistant prostate cancer (mCRPC) provide latitude in designing treatment plans that meet patients’ medical needs and personal ...of ... See full document

... and radium-223 – these treatments are not ...of treatment selection and sequencing is therefore to optimize QOL as well as ...the treatment of mCRPC were developed simultaneously; therefore, ... See full document

... As ALP levels can reflect bone activity, we postulated that the pain response during Ra223 treatment may correlate with ALP response. Our study failed to show such a relation- ship, which is the second major ... See full document

... placebo. Prostate-specific antigen (PSA) response rate (defined as a >30% decline from base- line) was 21% and alkaline phosphatase (ALP) response rate (defined as a decline >30%) was ... See full document

... Ra223 is amongst six different treatment modalities that prolong the survival and improve the quality of life of men with mCRPC. 3 While the use of different control arms and targeting of different disease stages ... See full document

... Efficacy analyses for opioid subgroups were based on the intent-to- treat (ITT) population, including all randomized patients. Safety analyses were based on the safety population, including all patients who received at ... See full document

... death. Radium-223 dichloride is a calcium-mimetic agent that specifically targets bone ...lesions. Radium-223 dichloride has been approved for the treatment of metastatic ... See full document

... of radium-223 at a dose of 50 kBq/kg every 4 weeks in addition to best standard of care or six cycles of placebo every 4 weeks in addition to best standard of ...of radium-223 and the trial ... See full document

... Nuclear medicine treatment of cancer exploits the targeting of radiation through transporters or receptors on tumor cells. Building on this principle, the complexity of therapeutic radiopharmaceuticals ... See full document

... In total, 24 Pain group patients (55%) showed an improvement of at least 2 units on worst pain score, and 23 (52% of all Pain group patients, 95%CI 38%-67%) had a pain response. Four (17%) of the 23 pain responders also ... See full document

... with radium-223 in our single center ...of castration-resistant disease was defined as a serum testos- terone level of 50 ng/dL or less ...during treatment consisting of androgen- ... See full document

... randomized 921 patients in a 2:1 ratio to receive six 4-weekly intravenous injections of radium-223 (50 kBq/kg) or placebo. Eligible patients had progressive symptomatic CRPC with two or more bone ... See full document

... in prostate-specific antigen (PSA) levels, overall disease progression, or overall ...supports metastatic cancer and promotes treatment ... See full document

... with prostate cancer each year and it is the most frequently diagnosed cancer in men in the developed world ...When prostate cancer metastasizes, it preferentially spreads to ...of ... See full document

... the treatment of CRPC and the improved understanding of the molecular biology mechanisms driving disease progression beyond castration, the improvement of mechanisms for tissue acquisition and molecular ... See full document

... suppressor cells (MDSCs) in metastatic castration-resistant prostate cancer (CRPC) patients 20. (PTS)[r] ... See full document

... CRPC. Treatment deci- sions for patients with advanced prostate cancer, which were largely palliative, have now changed in the light of TAX 327 and SWOG 9916 ...the metastatic setting should ... See full document

... The treatment was in continuous 28-d cycles ...to prostate-specific antigen (PSA) progression according to Prostate Cancer Working Group 2 criteria, time to initiation of cytotoxic ... See full document